Listen and follow our podcasts on:

This educational programme is supported by an Independent Medical Education Grant from Bayer

In this SARCOMA CONNECT podcast, Prof. Robert Maki and Prof. Silvia Stacchiotti discuss recent updates in Bone Sarcoma guidelines. During the podcast they highlight key topics:

  • Updates in the latest ESMO and NCCN Guidelines for Bone Cancer
  • Compare and contrast the guidelines
  • Highlight key clinical practice learning points.
  • Latest clinical trial data, with a focus on osteosarcoma and Ewing sarcoma, but including chordoma and Giant Cell Tumour of bone,
  • What they mean for clinical practice and patients.

Dr Maki is a medical oncologist who has focused for over 20 years to understand tumors arising from connective tissues, which include sarcomas and other aggressive tumors that do not metastasize, such as desmoid tumors. These tumors represent less than 1% of all cancers that happen in adults. I work with patients with these diagnoses to find the right treatment for the 70 or more types of bone and soft tissue sarcomas and other soft tissue tumors. As part of this work, I also reserach new medications for cancer in general, a field called developmental therapeutics. In my research, I seek to find new medications that may be useful for sarcoma patients, and try to figure out why they work or not. I work closely with colleagues at Penn Medicine, the Children's Hospital of Philadelphia, and with other national and international teams of researchers such as SARC, the Sarcoma Alliance for Research through Collaboration, to improve the understanding and treatment of sarcomas.

Prof. Robert Maki has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

 American Society for Clinical Oncology,  Bayer, Deciphera, Kayopharm, Peel Therapeutics and Tracon.

A medical oncologist, Silvia Stacchiotti works in the Adult Mesenchymal and Rare Tumor Medical Treatment Unit, Cancer Medicine Department, Fondazione IRCCS Istituto Nazionale Tumori (INT), Milano, Italy. Dr Silvia Stacchiotti received his medical degree in 1993 in Milan, and trained at the INT. She is board certified in Medical Oncology. She has four children. She is involved in all institutional research activities on adult bone and soft tissue sarcomas (STS), including GIST. This includes neoadjuvant therapies in extremities and retroperitoneal STS, identification of new targets and new anticancer treatments for specific sarcoma types, studies on the immune-profile of sarcomas as well as on mechanisms of resistance to therapy and the development of preclinical models of sarcomas. She collaborates to the Italian Network on Rare Tumors. She is particularly dedicated to ultra-rare sarcomas, among which chordoma, chondrosarcoma, giant cell tumor of the bone, extraskeletal myxoid chondrosarcoma, alveolar soft part sarcoma, clear cell sarcoma, dermatofibrosarcoma protuberans, solitary fibrous tumor, PEComa, vascular tumors, epithelioid sarcoma, desmoid tumor, tenosynovial giant cell tumor. She is the Principal Investigator of several Italian and International trials on sarcomas. She is the current president of the Italian Sarcoma Group (ISG). She is the faculty coordinator of the Sarcoma track of the European Society for Medical Oncology (ESMO) and the subject editor of the ESMO guidelines committee for sarcoma and GIST. She is a member of the Board of Directors of the Connective Tissue Oncology Society (CTOS). She is included in the list of European Medical Agency (EMA) external experts. She is the chair of the systemic therapy subcommittee of the EORTC Soft Tissue and Bone Sarcoma Group. She collaborates with several sarcoma Patients Advocacy Groups, among which the Chordoma Foundation, the Desmoid Tumor Research Foundation, the EHE Foundation, in which she serves as a member of the respective medical advisory boards. She has authored more than 200 scientific publications. She serves on the editorial board of European Journal of Cancer and Cancer

Prof. Silvia Stacchiotti has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Aadi, Amgen Dompé,  Advenchen, Astex Pharmaceuticals, Bayer, Bavarian, Blueprint, Deciphera, Eli Lilly, Epizyme Inc., Dalichi Sankyo, Glaxo Smith Kline, Hutchinson, Ikena, Karyopharm, Maxivax, Novatis, Pfizer, PharmaMar, Rain Therapeutic and SpringWorks. 

Programme summary
Listen to the podcast now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
SARCOMA CONNECT

SARCOMA CONNECT is an initiative of COR2ED, supported by Independent Medical Educational Grants from Bayer and Karyopharm Therapeutics.

Meet the experts

Other programmes of interest

Podcast
Oncology 
Colorectal cancer: understanding the needs of different patient populations

Exploring the impacts of age, ethnicity, socioeconomic status, and access to healthcare on patients with colorectal cancer

Experts
Prof. Tanios Bekaii-Saab, Deneen Richmond, Oncology Brothers (Moderators)
Endorsed by
COLONTOWN
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Podcast
Oncology 
Interpreting real-world evidence in later-line mCRC

Aligning real-world evidence with clinical trial data 

Experts
Prof. Tanios Bekaii-Saab, Prof. Shubham Pant
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Podcast

Episode

1

of 3

episode
Oncology 
Cáncer de próstata: Dificultades en la fase preanalítica y pruebas de biomarcadores (Spanish)

Moderado por los Oncology Brothers. Episodio 1 de una serie de podcast de video de 3 partes.

Experts
Dr Alexander Wyatt, Dr Petros Grivas, Oncology Brothers (Moderators)
Endorsed by
NASPCC AMP
  • download Downloadable
    Resources
  • clock 30 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.
Podcast

Episode

3

of 3

episode
Oncology 
Câncer de Ovário: Desafios da fase pré-analítica e teste de biomarcadores (Portuguese)

Moderado pelos Oncology Brothers. Episódio 3 da série de podcasts em vídeo de 3 partes

Experts
Assoc. Prof. Martina Murphy, Assoc. Prof. Caterina Marchiò, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 32 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.
Podcast

Episode

3

of 3

episode
Oncology 
Cáncer de ovario: Dificultades en la fase preanalítica y pruebas de biomarcadores (Spanish)

Moderado por los Oncology Brothers. Episodio 3 de una serie de podcast de 3 partes.

Experts
Assoc. Prof. Martina Murphy, Assoc. Prof. Caterina Marchiò, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 32 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.
Podcast

Episode

2

of 3

episode
Oncology 
Câncer de Pulmão: Desafios da fase pré-analítica e teste de biomarcadores (Portuguese)

Moderado pelos Oncology Brothers. Episódio 2 da série de podcasts em vídeo de 3 partes

Experts
Dr Bruna Pellini, Dr Semir Vranić, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.